RefleXion Medical
By leveraging positron emission tomography (PET), the gold standard in cancer imaging and staging in a novel way, RefleXion’s patented technology* causes tumors to continuously signal their location during radiotherapy.
Launch date
Employees
Market cap
-
Enterprise valuation
$550m (Public information from Nov 2023)
Hayward California (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$11.6m | Series A | ||
$46.0m | Series B | ||
$100m | Series C | ||
$60.0m | Debt | ||
* | $110m Valuation: $485m | Series D | |
$40.0m Valuation: $550m | Series D | ||
* | $80.0m Valuation: $550m | Late VC | |
* | $125m | Debt | |
* | $105m Valuation: $550m | Late VC | |
Total Funding | $493m |
Recent News about RefleXion Medical
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.